Description

Plinabulin (NPI-2358) is a potent, synthetic small-molecule vascular disrupting agent (VDA) and immunomodulator derived from the natural product halimide. Its core value proposition lies in its dual mechanism of action, which targets both tumor vasculature and immune checkpoint pathways, offering a novel approach in oncology research and therapeutic development. This compound is essential for pharmaceutical R&D teams, academic researchers, and contract research organizations (CROs) focused on developing next-generation cancer therapies, particularly in areas of drug resistance and combination treatments.

Application

• Oncology Research & Drug Discovery: Primary application as a reference standard and active pharmaceutical ingredient (API) in preclinical and clinical studies for various solid tumors and hematologic malignancies.
• Vascular Disrupting Agent (VDA) Studies: Used to investigate mechanisms of tumor blood vessel collapse and the resulting anti-tumor effects.
• Immuno-Oncology Research: Employed in studies exploring its immunomodulatory effects, including dendritic cell maturation and T-cell activation, often in combination with checkpoint inhibitors.
• Chemical Biology & Mechanism of Action (MOA) Studies: Serves as a critical tool for studying tubulin binding, GEF-H1 pathway activation, and downstream cellular effects.
• Formulation Development: Used in the development of injectable formulations, leveraging its solubility profile for parenteral delivery.
• Process Chemistry & Analytical Method Development: Acts as a high-purity standard for developing and validating synthesis routes, purification processes, and QC analytical methods (HPLC, MS, NMR).

Basic Information

Product Name	Plinabulin (NPI-2358)
CAS No.	714272-27-2
Molecular Formula	C₂₉H₃₁N₅O₅
Molecular Weight	529.59 g/mol
Synonyms	NPI-2358; (3S,5Z,8S,9S,11E)-14-(Cyclohexylmethyl)-8,9,15-trihydroxy-11-(1H-indol-3-ylmethylidene)-5-methyl-1,4,8,10-tetraazabicyclo[10.3.0]pentadeca-5,11-diene-2,6,13-trione; BPI-2358; 714272-27-2; UNII-5K0J7VHU3B
EINECS	Contact for details

Quality Control

Our Plinabulin (NPI-2358) is manufactured under strict quality management systems. Each batch undergoes comprehensive analytical testing to ensure identity, purity, and consistency, meeting the stringent requirements for pharmaceutical research. A detailed Certificate of Analysis (COA) is provided with each shipment, documenting specifications including assay (HPLC), chiral purity, residual solvents, and related substances. We support compliance with cGMP guidelines for API manufacturing where required.

Storage

Preserve in a tightly closed container, protected from light. Store at controlled room temperature, typically between 15-25°C, in a dry environment. The product is light-sensitive and should be handled under appropriate conditions to maintain stability.

Specification

Item	Specification
Appearance	White to off-white solid
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥98.0%
Chiral Purity (Chiral HPLC)	≥99.0%
Related Substances (HPLC)	Total impurities ≤2.0%; Any single unknown impurity ≤0.5%
Residual Solvents (GC)	Complies with ICH Q3C guidelines
Water Content (KF)	≤0.5%
Heavy Metals	≤20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.